Patents Assigned to Intrexon Corporation
  • Leafthopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
    Patent number: 8680249
    Abstract: The present invention relates to a novel isolated leafhopper ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the leafhopper ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate leafhopper ecdysone receptor activity.
    Type: Grant
    Filed: September 7, 2007
    Date of Patent: March 25, 2014
    Assignee: Intrexon Corporation
    Inventor: Subba Reddy Palli
  • MEK Ligands and Polynucleotides Encoding MEK Ligands
    Publication number: 20140073028
    Abstract: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate MEK activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands.
    Type: Application
    Filed: October 4, 2013
    Publication date: March 13, 2014
    Applicant: Intrexon Corporation
    Inventors: David BACHINSKY, Jonathan Carson, Amy Atzel, Thomas Reed
  • Substitution mutant receptors and their use in a nuclear receptor-based inducible gene expression system
    Patent number: 8669051
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to novel substitution mutant receptors and their use in a Group H nuclear receptor-based inducible gene expression system and methods of modulating the expression of a gene in a host cell for applications such as gene therapy, large scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Grant
    Filed: August 20, 2007
    Date of Patent: March 11, 2014
    Assignee: Intrexon Corporation
    Inventors: Subba Reddy Palli, Mohan Basavaraju Kumar, Dean Ervin Cress, Ted Tsutomu Fujimoto
  • Oxadiazoline ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
    Patent number: 8669072
    Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.
    Type: Grant
    Filed: August 13, 2007
    Date of Patent: March 11, 2014
    Assignee: Intrexon Corporation
    Inventors: Robert Eugene Hormann, Orestes Chortyk, Dat Phat Le
  • Steroidal Ligands and Their Use in Gene Switch Modulation
    Publication number: 20140057349
    Abstract: The present invention relates to steroidal ligands for use in nuclear receptor-based inducible gene expression systems. The invention further relates to methods of modulating the expression of genes of interest with a system containing one or more nuclear receptor complexes and one or more steroidal ligands. Further aspects include ligand compositions including therapeutic compositions.
    Type: Application
    Filed: July 22, 2013
    Publication date: February 27, 2014
    Applicant: Intrexon Corporation
    Inventors: Robert E. HORMANN, Silvia Lapenna, Laurence Neil Dinan
  • Bioavailable Diacylhydrazine Ligands for Modulating the Expression of Exogenous Genes via an Ecdysone Receptor Complex
    Publication number: 20140045903
    Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.
    Type: Application
    Filed: July 30, 2013
    Publication date: February 13, 2014
    Applicant: Intrexon Corporation
    Inventors: Robert Eugene HORMANN, David W. Potter, Orestes Chortyk, Colin M. Tice, Glenn Richard Carlson, Andrew Meyer, Thomas R. Opie
  • Methods of making modular fusion protein expression products
    Patent number: 8603807
    Abstract: The invention relates to methods of making modular chimeric protein expression products and compositions utilized in the methods. In particular, the invention relates to sequential, directional cloning of polynucleotides encoding polypeptide modules. Each clonable element or module contains an open reading frame of interest flanked by predetermined restriction sites. The methods include using modules and vectors containing these modules as starting materials for recombinant DNA techniques. One advantage of the invention is that it allows for many variations of fusion proteins to be made quickly and easily without needing to design and evaluate each subsequent cloning step.
    Type: Grant
    Filed: October 19, 2006
    Date of Patent: December 10, 2013
    Assignee: Intrexon Corporation
    Inventor: Thomas D. Reed
  • Non-human organism comprising a gene expression modulation system encoding a chimeric retinoid X receptor
    Patent number: 8598409
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Grant
    Filed: August 24, 2007
    Date of Patent: December 3, 2013
    Assignee: Intrexon Corporation
    Inventors: Marianna Zinovievna Kapitskaya, Subba Reddy Palli
  • MEK ligands and polynucleotides encoding MEK ligands
    Patent number: 8575304
    Abstract: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate MEK activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands, homopolyligands, and heteropolyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands.
    Type: Grant
    Filed: March 27, 2008
    Date of Patent: November 5, 2013
    Assignee: Intrexon Corporation
    Inventors: Thomas Reed, Amy Atzel, David Bachinsky, Jonathan Carson
  • Multiple Inducible Gene Regulation System
    Publication number: 20130276156
    Abstract: The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes.
    Type: Application
    Filed: September 13, 2012
    Publication date: October 17, 2013
    Applicant: Intrexon Corporation
    Inventors: Tarlochan Singh DHADIALLA, Dean Ervin Cress, Glenn Richard Carlson, Robert Eugene Hormann, Subba Reddy Palli, Arthur John Kudla, Ronald Phillip Herzig, JR., Mohan Philip
  • Multiple Inducible Gene Regulation System
    Publication number: 20130267023
    Abstract: The present invention relates to the field of biotechnology or genetic engineering. More specifically, the present invention relates to a multiple inducible gene regulation system that functions within cells to simultaneously control the quantitative expression of multiple genes.
    Type: Application
    Filed: March 27, 2012
    Publication date: October 10, 2013
    Applicant: Intrexon Corporation
    Inventors: Tarlochan Singh DHADIALLA, Dean Ervin Cress, Glenn Richard Carlson, Robert Eugene Hormann, Subba Reddy Palli, Arthur John Kudla, Ronald Phillip Herzig, JR., Mohan Philip
  • Endoplasmic Reticulum Localization Signals
    Publication number: 20130253167
    Abstract: The invention relates to cellular localization signals. In particular, the invention relates to endoplasmic reticulum localization signals in monomeric or multimeric form. The localization signals are utilized as research tools or are linked to therapeutics. Disclosed are methods of making and using polypeptides and modified polypeptides as signals to localize therapeutics, experimental compounds, peptides, proteins and/or other macromolecules to the endoplasmic reticulum of eukaryotic cells. The polypeptides of the invention optionally include linkage to reporters, epitopes and/or other experimental or therapeutic molecules. The invention also encompasses polynucleotides encoding the localization signals and vectors comprising these polynucleotides.
    Type: Application
    Filed: February 9, 2012
    Publication date: September 26, 2013
    Applicant: Intrexon Corporation
    Inventor: Thomas D. REED
  • mTOR Ligands and Polynucleotides Encoding mTOR Ligands
    Publication number: 20130244329
    Abstract: The invention relates to kinase ligands and polyligands. In particular, the invention relates to ligands, homopolyligands, and heteropolyligands that modulate mTOR activity. The ligands and polyligands are utilized as research tools or as therapeutics. The invention includes linkage of the ligands and polyligands to a cellular localization signal, epitope tag and/or a reporter. The invention also includes polynucleotides encoding the ligands and polyligands.
    Type: Application
    Filed: June 7, 2012
    Publication date: September 19, 2013
    Applicant: Intrexon Corporation
    Inventors: Thomas David REED, Amy H. Atzel
  • Steroidal ligands and their use in gene switch modulation
    Patent number: 8536354
    Abstract: The present invention relates to steroidal ligands for use in nuclear receptor-based inducible gene expression systems. The invention further relates to methods of modulating the expression of genes of interest with a system containing one or more nuclear receptor complexes and one or more steroidal ligands. Further aspects include ligand compositions including therapeutic compositions.
    Type: Grant
    Filed: March 16, 2009
    Date of Patent: September 17, 2013
    Assignee: Intrexon Corporation
    Inventors: Robert E. Hormann, Silvia Lapenna, Laurence Neil Dinan
  • Chimeric Retinoid X Receptors and Their Use in a Novel Ecdysone Receptor-Based Inducible Gene Expression System
    Publication number: 20130232588
    Abstract: This invention relates to the field of biotechnology or genetic engineering. Specifically, this invention relates to the field of gene expression. More specifically, this invention relates to a novel ecdysone receptor/chimeric retinoid X receptor-based inducible gene expression system and methods of modulating gene expression in a host cell for applications such as gene therapy, large-scale production of proteins and antibodies, cell-based high throughput screening assays, functional genomics and regulation of traits in transgenic organisms.
    Type: Application
    Filed: September 14, 2012
    Publication date: September 5, 2013
    Applicant: Intrexon Corporation
    Inventors: Marianna Zinovievna KAPITSKAYA, Subba Reddy Palli
  • Bioavailable diacylhydrazine ligands for modulating the expression of exogenous genes via an ecdysone receptor complex
    Patent number: 8524948
    Abstract: The present invention relates to non-steroidal ligands for use in nuclear receptor-based inducible gene expression system, and a method to modulate exogenous gene expression in which an ecdysone receptor complex comprising: a DNA binding domain; a ligand binding domain; a transactivation domain; and a ligand is contacted with a DNA construct comprising: the exogenous gene and a response element; wherein the exogenous gene is under the control of the response element and binding of the DNA binding domain to the response element in the presence of the ligand results in activation or suppression of the gene.
    Type: Grant
    Filed: September 23, 2011
    Date of Patent: September 3, 2013
    Assignee: Intrexon Corporation
    Inventors: Robert Eugene Hormann, David W. Potter, Orestes Chortyk, Colin M. Tice, Glenn Richard Carlson, Andrew Meyer, Thomas R. Opie
  • REGULATORY ELEMENT FOR HETEROLOGOUS PROTEIN PRODUCTION IN THE FRUITING BODY OF FILAMENTOUS FUNGI
    Publication number: 20130219554
    Abstract: The present invention provides compositions and methods for regulating expression of nucleotide sequences in fungi. Compositions are novel nucleotide sequences for a tissue preferred promoter isolated from the Agaricus bisporus lectin gene. The sequences drive expression preferentially to fruit body tissue. A method for expressing a nucleotide sequence in fungi using the regulatory sequences disclosed herein is provided. The method comprises transforming a fungal cell to comprise a nucleotide sequence operably linked to one or more of the regulatory sequences of the present invention and regenerating a stably transformed fungus from the transformed cell.
    Type: Application
    Filed: August 30, 2011
    Publication date: August 22, 2013
    Applicant: INTREXON CORPORATION
    Inventors: Zhixin Shi, Jack Q. Wilkinson, Donald S. Walters, C. Peter Romaine
  • Vectors Conditionally Expressing Therapeutic Proteins, Host Cells Comprising the Vectors, and Uses Thereof
    Publication number: 20130195800
    Abstract: This invention relates to the field of therapeutics. Most specifically, the invention provides methods of generating conditionally expressing vectors for one or more immunomodulators under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals. These vector may be provided to treat a variety of disorders, e.g., neoplastic disorders, through direct injection or through in vitro engineered cells, such as dendritic cells.
    Type: Application
    Filed: March 23, 2011
    Publication date: August 1, 2013
    Applicant: Intrexon Corporation
    Inventors: Jeremiah F. Roeth, Charles C. Reed, Brandon Cuthbertson, Sunil Chada, William E. Fogler
  • Leafhopper ecdysone receptor nucleic acids, polypeptides, and uses thereof
    Patent number: 8497093
    Abstract: The present invention relates to a novel isolated leafhopper ecdysone receptor polypeptide. The invention also relates to an isolated nucleic acid encoding the leafhopper ecdysone receptor polypeptide, to vectors comprising them and to their uses, in particular in methods for modulating gene expression in an ecdysone receptor-based gene expression modulation system and methods for identifying molecules that modulate leafhopper ecdysone receptor activity.
    Type: Grant
    Filed: August 16, 2011
    Date of Patent: July 30, 2013
    Assignee: Intrexon Corporation
    Inventor: Subba Reddy Palli
  • Engineered Dendritic Cells and Uses for the Treatment of Cancer
    Publication number: 20130149290
    Abstract: This invention provides the field of therapeutics. Most specifically present invention provides methods of generating in vitro engineered dendritic cells conditionally expressing interleukin-12 (IL-12) under the control of a gene expression modulation system in the presence of activating ligand and uses for therapeutic purposes in animals including human.
    Type: Application
    Filed: January 9, 2013
    Publication date: June 13, 2013
    Applicants: University Of Pittsburgh-Of The Commonwealth System Of Higher Education, Intrexon Corporation
    Inventors: Intrexon Corporation, University Of Pittsburgh-Of The Commonwealth System Of Higher Education